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Abstract Traditional diagnostic methods such as clinical
assessment, histopathological examination and imaging
techniques are limited in their capacity to provide infor-
mation on prognosis and treatment choice of head and neck
cancer. In recent years, molecular techniques have been
developed that enabled us to get more insight into the
molecular biological cellular pathways underlying tumor
progression and metastasis. Correlation of these molecular
changes with clinical events has been explored. However,
consistently useful markers have not been identified yet,
although many promising developments are in progress. It
may be expected that in the near future, molecular markers
will be useful for clinical purposes. In this paper, an
overview will be given of the several molecular techniques
that may have potential to be introduced in clinical practice
in the management of head and neck squamous cell
carcinoma.
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Introduction
Despite major advancements in cancer diagnosis and
treatment, the survival rate for patients with head and neck
squamous cell carcinoma (HNSCC) has only marginally
improved over the past few decades. Our ability to prog-
nosticate HNSCC patients is especially poor owing to
variations in the biological behavior of tumors and inade-
quacies of the present staging system. At present, histo-
pathological features, such as tumor site, T classification,
the presence and extent of nodal metastasis, tumor volume
and thickness provide the most reliable tumor-related
determinants of prognosis, and influence treatment in
patients with head and neck cancer. On the basis of these
clinical and pathologic parameters, the most likely clinical
outcome can be estimated in an attempt to make the most
appropriate decision for patient management.
Recent advances in basic research and genomics have
improved our understanding of the molecular processes
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governing head and neck cancer progression [1, 2]. It could
be expected that the identification of molecular signatures
and understanding mechanisms of tumor progression may
facilitate the identification of new predictive and prog-
nostic markers and new therapeutic targets for the treat-
ment of this cancer. In addition, these molecular markers
might allow very sensitive detection of minimal residual
cancer cells in the various compartments of the body.
RT-PCR approaches have been described that allow the
detection of a single tumor cell in 20 million normal white
blood cells [3]. In 2005, Rodrigo et al. [4] reviewed the
potential of the new molecular diagnostic methods in head
and neck cancer. At that time, few of these methods were
translated into improved patient care or better technology
for molecular diagnostics. In the last years, the widespread
use of high-throughput technologies (especially micro-
arrays) has generated a considerable amount of information
about the potential application of these techniques as pre-
dictive or prognostic markers. However, although the
technological possibilities seem endless, the practical
implementation of these assays in the clinic still appears to
be some way into the future. Moreover, many of the
approaches developed do have prognostic impact, but
usually not to an extent that it can be used for the clinical
management of the individual patient.
Therefore, in the present article, we review the emerging
information in high-throughput (‘‘molecular’’) diagnostic
assays in HNSCC from a critical perspective.
Molecular diagnostic techniques
Currently, it is widely accepted that cancer arises as a
result of the accumulation of genetic and epigenetic
alterations in oncogenes and tumor suppressor genes,
causing clonal evolution of the cells with most malignant
phenotype. Some of these alterations occur specifically in
the genes that play a crucial role in the normal behavior
of the cell, but often these changes appear in less crucial
sequences and are, therefore, a mere reflection of the
genetic instability of the tumors [5]. Hence, tumor cells
harbor specific clonal genetic changes that can be used as
molecular markers for the detection of cancer cells in
clinical samples. In addition to these tumor-specific
genetic alterations, tissue-specific markers can also be
exploited, but with two important considerations: (1) the
marker should still be expressed homogeneously in the
tumors derived from the tissue; and (2) the marker should
preferably not be expressed in the clinical sample of
interest. The choice of a particular marker or assay
depends on the necessary sensitivity and specificity of the
assay, the origin of the clinical sample, and the labori-
ousness of the assay [3].
The genetic analysis of cancers reached a crescendo
with the completion of the Human Genome Project along
with the development of high-throughput genome-wide
analytic techniques. Nowadays, these encompass the
complete sequencing of all protein encoding genes and
high-resolution array methods that allow in identifying
amplifications and deletions up to the 100 base pair level.
These analyses have helped to shape our understanding of
human malignancies generally, and head and neck cancers
specifically.
Accurately identified biomarkers may provide new
avenues for early cancer detection, and constitute targets
for cancer risk assessment. Biomarkers are compromised
by their insufficient diagnostic sensitivity and specificity;
and are thus not used for definitive diagnosis, but as an
auxiliary approach to assist in clinical decision-making.
Emerging high-throughput technologies, including micro-
array and mass spectrometry, provide global information to
observe genetic and proteomic alterations and to facilitate
the discovery of new biomarkers with improved sensitivity
and specificity. Moreover, the development of powerful
bioinformatics methodologies has contributed to the mea-
surement of thousands of gene expressions simultaneously
[6–8]. Advances in proteomics and genomics have con-
tributed to the understanding of the pathophysiology of
neoplasia, cancer diagnosis and anticancer drug discovery.
The powerful ‘omics’ technologies have opened new ave-
nues towards biomarker discovery, identification of sig-
naling pathways associated with cell growth, cell death,
cellular metabolism and early detection of cancer. Analysis
of tumor-specific ‘‘omics’’ profiles provided a unique
opportunity to diagnose, classify, and detect malignant
disease; to better understand and define the behavior of
specific tumors; and to provide direct and targeted therapy
[9].
Molecular techniques for lymph node metastasis
The presence or absence of metastatic disease in cervical
lymph nodes is the only most significant determinant of the
subsequent therapy and prognosis for patients with head
and neck cancer [10]. Given the impact of nodal status on
treatment and prognosis, accurate staging of cervical lymph
nodes is critical. However, lymph nodes with micrometa-
static deposits cannot be detected preoperatively with
modern imaging techniques. Investigations, such as com-
puted tomography, magnetic resonance imaging and the
newer positron-emission tomography are relatively
expensive for the average-income patient in many coun-
tries and still are unable to reliably detect tumor deposits
smaller than about 3–5 mm [11]. Most reliably seems
ultrasound-guided fine-needle aspiration cytology, but the
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limitations in sensitivity have limited widespread use for
clinical decision-making. A new and promising develop-
ment is sentinel node biopsy, but this already necessitates a
surgical procedure. The limitations in staging have resulted
in the elective treatment of the neck, usually by selective
neck dissection in surgically treated patients, even in
patients without clinical or radiological evidence of lymph
node metastasis. Selective neck dissection adds limited, but
not neglectable morbidity [12], but it is an effective treat-
ment modality for early metastatic disease. Traditionally,
the chance on occult metastasis is estimated depending on
the site and the size of the primary tumor. Several other
histopathological factors have been identified that correlate
with a higher risk of occult metastasis, e.g. depth of
invasion [13–16].
In two ways, molecular techniques may contribute to
improvement of diagnostics. First, by better detection of
micrometastasis and second by improving the assessment
of the chance on clinically and radiologically occult
metastasis based on the features of the primary tumor [17].
Detection of micrometastasis
The incidence of occult sub-pathologic metastases in
patients with HNSCC has a mean incidence rate of 15.2%
[18]. In 2005, Yoshida et al. [19] investigated immuno-
histochemically the presence of occult metastases in cer-
vical lymph nodes from 24 patients with T2 N0 tongue
cancer and found micrometastasis in 58% of the patients.
Two lines of evidence suggest that routine light micro-
scopic histologic examination of neck dissection specimens
fails to detect a portion of these occult nodal metastases.
First, recurrence rates of approximately 10% are reported
in patients, who had histopathologically negative neck
dissection specimens, suggesting that metastases were
present, but not detected in the resected nodes [20].
However, recurrence can of course never occur in the
resected specimen, hence the recurrence has to be was in
non-resected nodes. So this phenomenon merely indicates
inaccurate staging in 10% due to incomplete resection of
all neck nodes. Second, retrospective studies using the
more sensitive yet laborious and expensive technique of
complete sectioning and immunohistochemistry of the
lymph nodes have found that 8–20% of patients with
HNSCC have nodal metastases that were not identified by
routine histopathologic examination [18]. In accordance,
Cote et al. [21] determined that the identification of regions
of metastasis by hematoxylin and eosin (H&E) staining of
negative lymph nodes on histologic examination required
the analysis of up to 144 slides/patients and, therefore, it is
not surprising that regions of metastasis within the lymph
node are not detected on routine histopathologic
examination. Therefore, serial microscopic sectioning of
the nodes may reveal micrometastases, but is impractical
for routine use. Recently, there has been considerable
progress in molecular diagnostics in these areas.
Several RNA-based markers were successfully used to
detect lymph node metastasis in head and neck cancer. In
2005, Elsheikh et al. [22] prospectively examined 48
patients with squamous cell carcinoma of the oral cavity,
with no palpable cervical lymph nodes who underwent an
elective supraomohyoid neck dissection. The incidence of
micrometastasis to lymph nodes was evaluated by patho-
logical examination as well as by molecular analysis
(CK20 mRNA expression). Of the 48 patients, 15 (31%) by
pathological analysis and 22 (46%) by molecular analysis
had lymph nodes positive for metastatic squamous cell
carcinoma. By molecular analysis, 5 (10%) of the 48
patients had involvement of sublevel IIB lymph nodes.
Using molecular analysis, the authors concluded that
clinically uninvolved sublevel IIB lymph nodes can be left
behind in elective supraomohyoid neck dissections in
patients with squamous cell carcinoma elsewhere in the
oral cavity, but should be included whenever tongue is the
primary site. In the same year, the same authors prospec-
tively investigated 31 patients with squamous cell carci-
noma of the larynx who underwent an elective lateral neck
dissection [23]. The incidence of micrometastasis to lymph
nodes in lateral neck dissection specimens was evaluated
by nested reverse-transcriptase-polymerase chain reaction
(RT-PCR) for cytokeratin 19 (CK19) and cytokeratin 20
(CK20), as well as by pathological examination. Nested
RT-PCR for CK19 and CK20 mRNA presented similar
results to each other, but these results differed from those
of routine pathological examination. Of the 31 patients, 6
(19%) by pathological analysis and 9 (29%) by molecular
analysis had lymph nodes positive for metastatic squamous
cell carcinoma. By molecular analysis, only 1 of the 31
patients had involvement of sublevel IIB lymph nodes.
Other investigators used the detection of CK14 mRNA by
RT-PCR as a marker of nodal metastases; they found that
CK14 RT-PCR is highly sensitive for detecting microme-
tastasis in lymph nodes that are negative by routine path-
ological examination, but with a relatively high false-
positive (50%) [24] rate. To avoid this problem, Yamazaki
et al. [25] determined p53 mutations in lymph nodes using
mutant allele specific amplification (MASA) in 21 patients
with oral squamous cell carcinoma. Of the 10 patients with
pathologic pN0, 4 (40%) were genetically positive; 44
(9%) of the 476 lymph nodes diagnosed as negative by
H&E staining were found to contain DNA with the same
mutation as detected in the primary tumors by the MASA
method. In addition, they observed that patients with
multiple or lower neck spread of micrometastases as
detected by this DNA assay have a poor prognosis. A
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potential problem in the use of DNA markers might be that
DNA is an extremely stable molecule and tumor-derived
DNA might find its way to the lymph nodes. This same
problem caused false-positive results when applied to the
detection of minimal disease in histopathologically tumor-
free surgical margins [3].
In addition at the RNA level, HNSCC-associated anti-
gens such as the E48 (hLy-6D) antigen allows the detection
of rare HNSCC cells in blood and bone marrow and, also in
lymph nodes and lymph node aspirates [26, 27].
A successful novel molecular diagnostic method for
rapid evaluation of lymph node metastasis in breast cancer
was indicated by Tsujimoto et al. [28]. They developed a
new intraoperative molecular diagnostic method, a one-
step nucleic acid amplification (OSNA) to quantitatively
measure CK19 mRNA expression. This assay consists of
a sample preparation and rapid gene amplification by
RT-LAMP (reverse-transcriptase loop-mediated isothermal
amplification)—the whole process takes only 30 min. In
the same way, Ferris et al. [29] using quantitative reverse
transcription-PCR (QRT-PCR) has identified four markers
that discriminated between positive and benign nodes with
accuracy greater than 97%. These markers were PVA
(pemphigus vulgaris antigen, also known as desmoglein-3),
SCCA1/2 (squamous cell carcinoma antigen, neutral and
acidic forms), PTHrP (parathyroid hormone-related pro-
tein), and TACSTD1 (also known as EPCAM). Moreover,
one of these markers, PVA, discriminated with 100%
accuracy between positive and benign lymph nodes. The
authors have developed a rapid quantitative QRT-PCR
assay for PVA that was incorporated into a completely
automated RNA isolation and QRT-PCR instrument (the
GeneXpert) developed for molecular diagnostic testing.
The automated analysis with PVA also provided perfect
discrimination between benign and malignant lymph
nodes, and was completed (from tissue to result) in about
30 min, thus demonstrating the feasibility of intraoperative
staging of HNSCC sentinel lymph nodes by QRT-PCR.
To develop a more efficient method for intraoperative
genetic detection of lymph node metastasis in HNSCC, a
total of 291 lymph nodes (59 patients) resected on SLN
biopsy for cN0 HNSCC or neck dissection for cN1/2
HNSCC were diagnosed by OSNA method using GD-100
[30]. The OSNA assay could be completed within 30 min
and the authors speculated that it showed high sensitivity
and specificity and can be used as a novel genetic detection
tool of lymph node metastasis in HNSCC patients.
The major problem of all of these methods is that they
do not easily fit in the routine logistics of the pathological
examination of the dissection specimens. Most molecular
methods work only reliably on fresh or frozen tissues and
require direct sampling from the surgical specimen. This is
more laborious and not easily planned in daily practice.
Alternatively, when methods would be suitable for analysis
on formalin-fixed paraffin-embedded samples, then addi-
tional cuts of the block need to be made. These molecular
methods seem, therefore, most suited for rapid and sensi-
tive analysis of subgroups of lymph node, such as the
sentinel lymph nodes.
Predictive tests for metastasis
For decades, predictors for nodal metastasis have been
sought, realizing that it would not be likely that a single
marker could predict this event which is the result of very
complex processes [17, 31]. However, numerous single
markers have been studied which showed a significant
correlation with nodal metastasis, with even very recent
examples [32]. However, no consistently relevant marker,
validated in larger series, has been established to date.
Recently, signatures have been identified for prediction
of lymph node metastasis in patients with head and neck
cancer based on the gene expression measurements in the
primary tumor [33, 34]. The potential clinical relevance of
these signatures resides in the difficulties for currently
diagnosing the absence of lymph node metastasis in
patients with head and neck cancer. Many patients with a
clinically negative neck receive inappropriate treatment
due to difficulties in preoperative detection of metastases in
the cervical lymph nodes [35, 36].
Roepman et al. [37] reported that their initially identified
set of predictive genes for the detection of lymph node
metastasis in patients with head and neck cancer is a subset
of a larger group of predictive genes. Using a resampling
approach, they have identified a large set of 825 genes that
can be used for prediction of lymph node metastasis. Based
on this group of genes, multiple predictive signatures can
be made with high-predictive accuracy. This is in agree-
ment with earlier observations [38] and for the head and
neck lymph node metastasis profile, Roepman et al. [37]
concluded that this is because there are many genes with a
similar expression pattern across the sample collection. In
contrast to other profiling studies, the predictive head and
neck lymph node metastasis signature has a more stable
gene composition, with a larger number of genes used in all
tested predictors. Strikingly, exclusion of the most fre-
quently occurring predictor genes could be compensated by
increasing the number of genes included in the signature.
Together, these analyses reveal that the most comprehen-
sive set of predictive genes that can be included in further
development of a diagnostic tool for the prediction of
lymph node metastasis.
The identified expression signature has the potential to
improve diagnosis and treatment of head and neck cancer,
particularly by reducing the number of patients given
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unnecessary neck surgery. The molecular signature has
been validated on an independent set of tumor samples to
make sure that the signature was not over-fitted on the
training samples and also works on new samples [34], as
has been previously advocated [39]. Independent validation
of this signature showed an accuracy of 100% for meta-
stasis-free predictions with an overall accuracy of 86% for
all samples. Importantly, no false-negative predictions
were made. Current clinical diagnosis of these patients
showed an overall accuracy of 68% and included five false-
negative predictions. The results of the validation set show
the clinical potential of the signature. A large multicenter
prospective validation study is required to confirm this
potential before the signature can be applied in patient
management, and currently carried out in the Netherlands.
Besides this study, several other HNSCC metastatic
signatures have been published [33, 34, 40–43]. These
HNSCC metastatic signatures were derived using several
different profiling platforms and analytical approaches (i.e.
supervised analysis of primary tumor signatures based on
the association with the presence of lymph node metasta-
ses, comparison of immortal vs. mortal HNSCC samples,
and comparison of metastases with paired primary tumors).
These diverse study designs can explain some of the dis-
crepancies seen in the direction of gene expression changes
and strengthen the significance of the genes that are inde-
pendently discovered in multiple studies. Similarities seen
between all these studies when pathways, rather than
individual gene products, were compared indicates that
high-level systems analysis will likely be essential for the
understanding and development of clinical applications
from primary gene expression data.
A potential problem that needs to be solved is that
specifically T1/T2 tumors in the oral cavity qualify for such
a staging procedure, and the amount of tumor sample is
then intrinsically limited. This might require that histo-
logical diagnosis needs to be carried out on frozen sections
in the future or the methods should allow to use FFPE
derived RNA. Alternatively, a profile might be derived on
the basis of genetic changes. DNA-based methods work
very reliably on FFPE specimens.
Molecular techniques for prognosis
Global genomic analyses have identified molecular subsets
of HNSCC, which may have prognostic implications [2,
33, 44, 45]. The challenge has been to reproduce prognostic
gene signatures. For example, two independent groups
have reported gene signatures that predict outcome in
breast cancers using gene arrays, one including 70 genes
and the other 76 genes [46, 47]. Interestingly, although
both sets of genes have been validated in independent
patient cohorts, there is relatively little overlap between the
gene sets. Similarly, the use of individual and combined
markers to predict outcome in HNSCC has shown con-
flicting results, as is well illustrated by the variable corre-
lation between p53 status and outcome reported by
different investigators [48–50]. The literature contains a
plethora of reports describing single molecular markers for
prognosis. Of these, few molecular markers have shown an
effect that is independent of conventional clinicopatho-
logical parameters and strong enough to influence clinical
decisions for the individual patient. In addition, most
studies include only small numbers of cases and seemingly
useful markers have only rarely been applied to a second
sample set, using the same methodology to verify the
results. So far, the majority of molecular markers evaluated
have been correlated with a good or bad prognosis in dif-
ferent studies. Probably, this reflects the different treat-
ments that the patients have had namely, surgery,
radiotherapy or combinations. Factors, such as the overall
treatment time, total radiation dose delivered, fraction size,
and delay to treatment also influence the final outcome;
hence, it is not surprising that studies utilising molecular
markers have often given contradictory results. As men-
tioned, the introduction of microarray technology was
expected to bring the power to identify molecularly defined
subclasses of tumour, which may predict clinical behavior.
However, at present, the differences between studies
involving similar tumour types can be as striking as the
similarities and our understanding of the biological rele-
vance of these array profiles is unclear. In addition, it has
been recently shown that differences in gene expression
related to aggressiveness of HNSCC disease are highly site
specific. Therefore, it is plausible that specific biological
mechanisms underlying tumor aggressiveness are heavily
influenced by the anatomic site of the primary tumor such
that different mechanisms offer advantage only within the
specific environment of a single anatomic site [2].
Several studies have used comparative genomic
hybridization (CGH) to categorize prognostic subgroups in
HNSCC. Three of these studies define individual prog-
nostic markers among a background of complex genetic
aberrations identified by CGH using well-defined statistical
methods [51–53]. These studies identified amplifications at
11q13 and 3q26–27 as markers of outcome. The 11q13
amplification has been well studied, with well-character-
ized oncogenes, including cyclin D1, cortactin, FADD,
and TAOS1 as putative targets for 11q13 amplification
[30, 54–57].
Amplification at 3q26.3 has also been a topic of sig-
nificant analysis, with several putative genes (including
PIK3CA, PKC-i, LAMP3, and eIF-5A2) identified at this
locus [58–62]. Similarly, gene array studies have delin-
eated putative prognostic subsets that predict outcome
Eur Arch Otorhinolaryngol (2010) 267:851–860 855
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[33, 44, 50]. Overall, studies using DNA-based assessment
have been more reproducible than those that profile using
mRNA-based gene arrays. Moreover, even though they are
provocative, none of these studies have been validated
sufficiently to allow use in routine clinical practice [63].
A very intriguing recent study indicated that HNSCCs
might be classified on the basis of their genetic profile. It is
well known that subgroups of head and neck cancer are
caused by infection of the human papillomavirus and these
tumors have in general a favorable prognosis. Importantly,
these tumors are very distinct at molecular level [45, 64].
However in the tumors that are negative for HPV also two
molecular subgroups are present, one with multiple genetic
changes (high CIN) and one with hardly any genetic
change (low CIN). This subclassification was related to
clinical and etiological factors, and even prognosis [65],
and might become highly relevant for the future.
Molecular techniques for early detection of malignant
disease
Recently, the extraordinary progress in nucleic acid-based
technologies has permitted the use of new diagnostic
methods. Nucleic acid-based markers may prove to be
valuable tools for early detection of cancer in asymptom-
atic individuals, for confirmation or exclusion of a cancer
diagnosis that is based on suspicious, but non-diagnostic
clinical material, for assessment of tumor burden in cancer
patients, and for assessment of response to preventive
approaches applied to healthy individuals who are at a high
risk for developing cancer [66].
Two DNA markers are relatively established; tumor-
specific p53 mutations and microsatellite alterations, which
can be exploited not only as tumor markers in HNSCC, but
also in many other tumor types [67–69]. K-ras mutations
are relatively rare in HNSCC, which prohibits their use in
molecular approaches. In other tumor types, K-ras muta-
tions are often used as markers [3]. The major limitation of
point mutations as molecular marker is that these need to
be analyzed for every single tumor sample. In addition, the
assays to detect these point mutations in a background of
normal DNA are laborious and require a lot of validation.
The major limitation of microsatellite markers is that these
can only be analyzed in more or less pure populations of
(pre)malignant cells. The relative imbalance of one allele
versus the other is considered as allelic loss using cut-off
points of 50%. Hence, when more than 50% of normal
DNA is present in a sample then they are always scored
negative. All molecular markers have their pros and cons
[3].
Saliva, the most accessible and non-invasive biofluid of
our body, harbors a wide spectrum of biological analytes
informative for clinical diagnostic applications. Park et al.
[70] have previously shown that a transcriptome is found in
saliva, and subpanels of these mRNAs can be used as oral
cancer biomarkers. In 2009, Park et al. [71] measured the
presence of microRNAs (miRNA) in saliva and determined
their potential as an additional set of oral cancer bio-
markers. A total of 314 miRNAs were measured using
reverse-transcriptase pre-amplification-quantitative PCR in
12 healthy controls. Degradation patterns of endogenous
and exogenous saliva miRNAs were measured at room
temperature over time. Selected miRNAs were validated in
saliva of 50 oral squamous cell carcinoma patients and 50
healthy matched control subjects. Two miRNAs, miR-125a
and miR-200a, were present in significantly lower levels in
the saliva of oral squamous cell carcinoma patients than
in control subjects, and the authors claimed that saliva
miRNAs can be used for oral cancer detection.
To explore the presence of informative protein bio-
markers in the human saliva proteome and to evaluate their
potential for detection of oral squamous cell carcinoma
(OSCC), Hu et al. [72] collected saliva samples from
patients with OSCC as well as from matched healthy
subjects. The proteins in pooled whole saliva samples were
profiled using shotgun proteomics based on C4-reversed-
phase liquid chromatography for pre-fractionation, and
immunoassays were used for validation of the candidate
biomarkers. Five candidate biomarkers were successfully
validated using immunoassays on an independent set of
OSCC patients and matched healthy subjects. A combi-
nation of these candidate biomarkers yielded a receiver-
operating characteristic value of 93%, sensitivity of 90%,
and specificity of 83% in detecting OSCC. The authors
concluded that patient-based saliva proteomics is a prom-
ising approach to search for OSCC biomarkers. The dis-
covery of these new targets may lead to a simple clinical
tool for the non-invasive diagnosis of oral cancer.
Discussion
Recent studies reported that microarray analysis has the
potential to change the diagnosis, classification and treat-
ment of cancer [73, 74]. Genome-wide gene expression
measurements have been used to identify expression sig-
natures capable of estimating a patient’s survival rate and
treatment response [75, 76] and to predict the metastatic
potential of primary tumors [34, 77]; such expression
profiles or signatures are expected to improve treatment
strategies by providing a more personalized therapy, based
for example on disease severity [78, 79]. As yet, the
majority of signatures are still in a developmental stage,
and generally not strong enough to be used for clinical
decision-making for the individual patient. Prospective
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validation of the first profiles has been launched at insti-
tutes in Europe and the United States [74]. These clinical
trials are done on a large number of patients, require a great
investment, and can only be carried out for profiles
showing strong potential.
Despite the possible benefits, genome-wide studies for
improvement of cancer diagnostics are currently being
critically evaluated [38, 80]. Several microarray studies
have identified gene sets capable of predicting a similar
prognostic outcome, such as survival rate of breast cancer
patients [42, 75, 77]. Interestingly, the overlap between the
predictive gene sets from these different studies is limited
to only a few genes. A recent analysis of microarray sig-
natures found that the gene composition of expression
signatures depends on the samples that were used for
building the signature [38]. Although the instability in gene
composition is not necessarily a negative property of sig-
natures, it does not simplify the task of choosing which
genes are the best candidates for designing a diagnostic
predictor.
In addition, to justify the more laborious and costly gene
signature as a classifier, it is not enough to show that it is
more significant than traditional risk factors in a multi-
variate regression analysis, such as a Cox-proportional
hazards model. For example, in breast cancer, Dunkler
et al. [81] showed that the 70-gene signature from van’t
Veer et al. [79] gave a moderate, but not significant
improvement in predictive accuracy in 234 patients from a
validation study, when added to the following prognostic
factors: age, nodal involvement, estrogen receptor status,
and tumor grade. Although much of the clinical interest has
focused on these gene signatures as predictive classifiers,
they are, of course, of considerable interest scientifically as
discovery tools, potentially identifying novel interventional
targets.
Conclusion
Cancer and HNSCC in particular is the result of dysregu-
lation of a complex system of molecular signaling path-
ways resulting from changes in DNA, RNA and
posttranscriptional molecules. Integration of information
from several different ‘‘omics’’ is needed for understanding
of the complex biology of cancer. Despite a substantial
research effort over 25 years, very few prognostic markers
and predictive assays have been established in routine
clinical oncology. Optimism and numerous significant
correlations cannot disguise the fact that this field still
needs to deliver on the promises. A major problem appears
to be the lack of a critical and consistent research track for
developing and testing candidate assays. Large collabora-
tive networks together with more awareness of appropriate
study designs and statistical methods will bring this field
forward. The most important ingredient will be large well-
conducted validation studies that will provide definitive
evidence on the value of specific diagnostic assays. After
validation, a future could be envisaged in which classifi-
cation systems and prognostic models contain molecular
information enabling improved treatment choices and
better outcomes.
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